Press What’s news at AbelsonTaylor Group
Select category
Top Innovations of 2024: AT Activate
Established in 2012, PM360 introduced the first-ever issue focused entirely on the pharma and healthcare marketing industry’s latest innovations. In 2024, AbelsonTaylor Group’s AT Activate was selected as a leader in Marketing Technology or Services. AT Activate, a full-service media agency, offers advanced end-to-end media strategy capabilities that make high-impact pharmaceutical advertising accessible to brands of all sizes. The solution is transforming the pharmaceutical advertising landscape for clients by leveraging data-driven insights, advanced technologies, and a dynamic approach to consumer, patient and healthcare professional (HCP) engagement. This strategy democratizes DTC high-cost TV buys with digital streaming for smaller brands or rare disease conditions with modest budgets. Read more at https://www.pm360online.com/pm360-2024-innovative-marketing-technology-or-services-at-activate/
Media Contact:
Recent Posts
Annual Report Healthcare Communications Agencies: Artificial Intelligence Brings Real Results
Leaders at AbelsonTaylor Group say the agency is harnessing AI-enabled messaging tools through a custom-built AI platform called Lexi. Lexi...
In the News Read more Annual Report Healthcare Communications Agencies: Artificial Intelligence Brings Real ResultsMedAdNews Agency Profile 2025: AbelsonTaylor Group
MedAdNews profiles AbelsonTaylor Group in its annual Agency Issue, highlighting AT Group’s “significant market wins,” new AI tools and initiatives...
In the News Read more MedAdNews Agency Profile 2025: AbelsonTaylor GroupAs Bluesky continues to grow, opportunities abound for pharma brands
With over 30 million users, Bluesky Social is quickly gaining steam. Associate Director of Engagement Helen Hoye recently spoke to...
In the News Read more As Bluesky continues to grow, opportunities abound for pharma brandsConnect with us
Find out what's top of mind for the people reimagining health and wellness advertising.